Cal-Maine Foods, Inc. to Participate in Oppenheimer's 22nd Annual Consumer Growth and E-Commerce ConferenceBusiness Wire • 05/31/22
Revitalist Addresses Opioid Epidemic Through Non-Medicative Interventions with TMS Representing a $195 Billion USD MarketBusiness Wire • 04/05/22
Cal-Maine Foods, Inc. Announces $82.0 Million for Capital Projects to Expand Company's Cage-Free Production CapabilitiesBusiness Wire • 03/30/22
Revitalist Increases Clinic Count to 10 with the Acquisition of a Virginia Ketamine ClinicBusiness Wire • 03/29/22
Revitalist Launches UNIT Initiative Working With Veteran and First Responder Non-Profits Across the United States Creating Nationwide GuidelinesBusiness Wire • 03/22/22
Cal-Maine Foods, Inc. Announces Release Date for Third Quarter Fiscal 2022 ResultsBusiness Wire • 03/15/22
Revitalist Reports Thirteen Months of Consecutive Monthly Visit Growth and a 427% Increase Year Over Year for February 2022Business Wire • 03/15/22
Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain SyndromesBusiness Wire • 03/01/22
Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical TrialsBusiness Wire • 02/24/22
Revitalist Partners with Herzing University to Develop Psychiatric Mental Health Professionals as Educational LeadersBusiness Wire • 02/17/22
Revitalist Partners with Retired Chief Master Sergeant to Release an Advocacy and Referral Campaign for Veterans Seeking Care From Veterans Health AdministrationBusiness Wire • 02/01/22
Revitalist Publishes Proprietary Diagnostic Tool After Receiving Certificate of Registration from The United States Copyright OfficeBusiness Wire • 01/27/22